The most advanced malaria vaccine candidate, RTS,S (also known as MosquirixTM), is a virus-like particle (VLP) comprising multiple copies of the P. falciparum circumsporozoite protein (Pf CSP) B cell repeats and some CD4+ and CD8+ T cell epitopes fused with recombinant hepatitis B surface antigen (RTS) and co-expressed with free hepatitis B surface antigen (S) (3), co-administered with AS01 adjuvant (4). This evidence concerns the gene CD4 and malaria.